CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell–mediated cytotoxicity

Park, Eun Jae; Jun, Hye Won; Na, Ik Ho; Lee, Hong Kyung; Yun, Jieun; Kim, Hyungsook; Kim, Youngsoo; Hong, Jin Tae; Han, Sang‐Bae

doi:10.1007/s12272-021-01365-z

Cited by 18 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FITC fluorescence intensity was analyzed with a FACSCalibur flow cytometer and Cell Quest Pro software (BD Biosciences, San Diego, CA, USA). 61 For the folate-competition study, the KB cells cultured in 1mM folate containing RPMI medium were seeded in 12-well plates (20×10 4 cells/well), and the cells were treated with Dox-loaded liposomal formulations for 5 h. The cells were washed thrice with cold PBS and the Dox fluorescence intensity was analyzed with a FACSCalibur flow cytometer and Cell Quest Pro software (BD Biosciences, San Diego, CA, USA). For cytotoxicity of the formulations, 10 4 of KB cells in 96-well plates were treated with Free Dox, Dox/NTL, Dox/FL-2K, Dox/FL-5K, or Dox/FL-10K (0.001–10 µg/mL) for 48 h. The cell viability was measured using CCK-8.…”

Section: Methodsmentioning

confidence: 99%

Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug

Lim¹,

Shin²,

Kang³

et al. 2023

IJN

View full text Add to dashboard Cite

Introduction Ligand-conjugated liposomes are promising for the treatment of specific receptor-overexpressing cancers. However, previous studies have shown inconsistent results because of the varying properties of the ligand, presence of a polyethylene glycol (PEG) coating on the liposome, length of the linker, and density of the ligand. Methods Here, we prepared PEGylated liposomes using PEG-linkers of various lengths conjugated with folate and evaluated the effect of the PEG-linker length on the nanoparticle distribution and pharmacological efficacy of the encapsulated drug both in vitro and in vivo. Results When folate was conjugated to the liposome surface, the cellular uptake efficiency in folate receptor overexpressed KB cells dramatically increased compared to that of the normal liposome. However, when comparing the effect of the PEG-linker length in vitro, no significant difference between the formulations was observed. In contrast, the level of tumor accumulation of particles in vivo significantly increased when the length of the PEG-linker was increased. The tumor size was reduced by >40% in the Dox/FL-10K-treated group compared to that in the Dox/FL-2K- or 5K-treated groups. Discussion Our study suggests that as the length of PEG-linker increases, the tumor-targeting ability can be enhanced under in vivo conditions, which can lead to an increase in the antitumor activity of the encapsulated drug.

show abstract

Section: Methodsmentioning

confidence: 99%

Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug

Lim¹,

Shin²,

Kang³

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

“…Quantitative PCR was performed with SYBR Green Master Mix (Elpis Biotech, Daejeon, Korea) in a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Determination of the relative mRNA level in a sample was based on its threshold cycle in comparison with that of the housekeeping gene for β-actin 42 . Primer sequences are listed in Supplementary Table 1 43 .…”

Section: Methodsmentioning

confidence: 99%

Mesenchymal stem cells enhance CCL8 expression by podocytes in lupus-prone MRL.Faslpr mice

Kim

Lee

Kim

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

Nephritis is common in systemic lupus erythematosus patients and is associated with hyper-activation of immune and renal cells. Although mesenchymal stem cells (MSCs) ameliorate nephritis by inhibiting T and B cells, whether MSCs directly affect renal cells is unclear. To address this issue, we examined the direct effect of MSCs on renal cells with a focus on chemokines. We found that expression of CCL2, CCL3, CCL4, CCL5, CCL8, CCL19, and CXCL10 increased 1.6–5.6-fold in the kidney of lupus-prone MRL.Faslpr mice with advancing age from 9 to 16 weeks. Although MSCs inhibited the increase in the expression of most chemokines by 52–95%, they further increased CCL8 expression by 290%. Using renal cells, we next investigated how MSCs enhanced CCL8 expression. CCL8 was expressed by podocytes, but not by tubular cells. MSCs enhanced CCL8 expression by podocytes in a contact-dependent manner, which was proved by transwell assay and blocking with anti-VCAM-1 antibody. Finally, we showed that CCL8 itself activated MSCs to produce more immunosuppressive factors (IL-10, IDO, TGF-β1, and iNOS) and to inhibit more strongly IFN-γ production by T cells. Taken together, our data demonstrate that MSCs activate podocytes to produce CCL8 in a contact-dependent manner and conversely, podocyte-derived CCL8 might potentiate immunosuppressive activity of MSCs in a paracrine fashion. Our study documents a previously unrecognized therapeutic mechanism of MSCs in nephritis.

show abstract

“…assessed various cell lines with variable sensitivity to NK-cell killing and found that SLAMF2 expression made the cells susceptible to killing. SLAMF2 increased the stability of the contact between the cancer cells and NK cells in live imaging experiments, which might explain this killing relationship ( 28 ).…”

Section: Slamf Receptors In Solid Tumorsmentioning

confidence: 99%

Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors

Gunes,

Rosen,

Shachar

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Recently, cancer immunotherapy has revolutionized cancer treatment. Various forms of immunotherapy have a manageable safety profile and result in prolongation of overall survival in patients with solid tumors, but only in a proportion of patients. Various factors in the tumor microenvironment play critical roles and may be responsible for this lack of therapeutic response. Signaling lymphocytic activation molecule family (SLAMF) members are increasingly being studied as factors impacting the tumor immune microenvironment. SLAMF members consist of nine receptors mainly expressed in immune cells. However, SLAMF receptors have also been detected in cancer cells, and they may be involved in a spectrum of anti-tumor immune responses. Here, we review the current knowledge of the expression of SLAMF receptors in solid tumors and tumor-infiltrating immune cells and their association with patient outcomes. Furthermore, we discuss the therapeutic potential of targeting SLAMF receptors to improve outcomes of cancer therapy in solid tumors. We believe the research on SLAMF receptor-targeted strategies may enhance anti-cancer immunity in patients with solid tumors and improve clinical outcomes.

show abstract

CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell–mediated cytotoxicity

Cited by 18 publications

References 48 publications

Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug

Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug

Mesenchymal stem cells enhance CCL8 expression by podocytes in lupus-prone MRL.Faslpr mice

Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors

Contact Info

Product

Resources

About